Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antiviral
Biotech
Atea's COVID antiviral fails to halt hospitalizations in phase 3
Atea Pharmaceuticals’ antiviral has failed another COVID-19 trial, but the biotech still holds out hope the candidate has a future in hepatitis C.
James Waldron
Sep 13, 2024 10:10am
Free-floating bacterial gene challenges biology's cardinal rules
Aug 14, 2024 10:31am
A seventh known patient seems cured of HIV
Jul 18, 2024 1:59pm
Poseida makes case for safety of Roche-partnered nonviral CAR-T
Dec 10, 2023 12:00pm
Pneumagen's flu antiviral stands up to human challenge study
Oct 2, 2023 4:00am
Potential for broad-spectrum antivirals could lie in host cells
Oct 12, 2022 12:21pm